Alnylam Stock Trades Below Its Pre-$1 Billion Buyback Price
Yahoo Finance ·
Today’s big story: Could Nvidia Stock Fall 50%? Follow The Cash Our look at what is driving Alnylam stock found a 5.4% jump on Friday, Nov 13 with no company news behind it. A reader asked for more, and the question owners need answered next is simple: can Alnylam’s $1 billion buyback put a floor under the stock? Not by itself, and the price has already said so. Alnylam announced the buyback after the close on Wednesday, Nov 4, with the stock at $161.08. Four sessions later, on Tuesday, Nov 10, it closed at $151.64, its lowest close in a year. At Monday’s close of $159.73 it still sits 0.84% below where it stood before the announcement. The buyback is real money. What it cannot do is replace the thing the market is actually pricing: how fast demand for Amvuttra, Alnylam’s main heart drug, grows from here. Big enough to matter. At Monday’s close, Alnylam’s market value was about $21.4 billion, so the program equals 4.7% of the company. At $159.73, $1 billion would buy about 4.7% of the shares outstanding at Sept 30. It is also easy to pay for. Alnylam held about $3,587 million in cash and short-term investments at Sept 30, so the buyback uses 27.9% of that pile. After subtracting debt, net cash was about $2,325 million, and the company produced about $612 million of free cash flow in the first nine months of 2026. Board chair Amy Schulman said the buyback and a move to new commercial leadership “demonstrate our conviction in Alnylam’s future.” So the money is there. The issue is that a buyback sets no price. It adds a buyer; it does not change what other buyers think the business is worth. The fall started on results day. The stock dropped 25.1% on Thursday, Oct 29, when CEO Yvonne Greenstreet said Alnylam is “not yet satisfied with the underlying demand growth we have observed”. From the last close before results to Monday, it is down 31.3%, and it sits 66.3% below its Dec 3, 2025 high close. Our look at what happened on results day covers that drop. Three details from the Oct 29 call explain why investors are cautious: Low end of the range. Alnylam expects 2026 sales of its TTR drugs (Amvuttra and Onpattro) at the low end of its $4.2 billion to $4.5 billion range. Part of Q3 growth was not demand. Of about $100 million of U.S. TTR growth from Q2 to Q3, $81 million was demand and $17 million came from higher wholesaler inventory, plus a one-time Medicaid benefit of about $10 million. Access headwinds. UnitedHealth made its first-line Amvuttra policy stricter in its Medicare Advantage business from Oct 1, which Alnylam said could delay new patients. A proposed CMS rule, if finalized as proposed, would substantially cut Medicare payment for Part B drugs bought through the 340B program, with a planned start of Jan 1, 2027. The one headline profit number is misleading. Q3 diluted EPS was $15.72, but that was inflated by a one-time non-cash tax benefit of about $1.9 billion. For 2025, diluted EPS was $2.33. None of this means the business is shrinking. Q3 TTR sales were $1.15 billion, up 59% from a year earlier. Total revenue rose 16.7%, a figure that also includes collaboration revenue. Amvuttra held about 24% of all TTR prescriptions through Q3, and an even larger share of new-to-brand prescriptions. On Nov 9, Alnylam presented five-year HELIOS-B data showing a sustained benefit in ATTR-CM; the stock still fell 3.2% the next session. Analysts’ average estimates imply 20.8% revenue growth in 2027, and the stock trades at 17.8 times the average 2027 EPS estimate. Our earlier piece on whether to buy the dip made that valuation case before the buyback; what has changed since is the buyback and a new one-year low after it. Recent daily moves are not a clean read. On Monday the stock fell 3.2% as the S&P 500 fell 1.9%, and Alnylam’s news feeds show no company announcement from Nov 13 to Nov 16. Since the Nov 10 low it has rebounded 5.3%. The clearer test comes with the Q4 and full-year results call in February, where Alnylam plans to share Phase 2 results for ALN-6400 and Phase 1 obesity data for ALN-2232. For owners, the numbers to watch are whether TTR sales growth comes from patients rather than inventory, and how the UnitedHealth policy and the 340B rule land. If demand growth picks up, we think the buyback becomes a useful support; if it does not, the price so far suggests the buyback alone will not hold the line. The idea underneath is to sell the thesis, not the price. A falling chart tells you about other investors; a change in Amvuttra demand would tell you about the company. An owner can write down now what would change the thesis, and a reader who wants in can set a buy price in advance rather than chase the next bounce. This stock just showed that even $1 billion of company money is not a floor. The calmer way to build wealth is a set of holdings where no single slide like this one can cost you a night’s sleep. Alnylam Pharmaceuticals is 66% below its highest close of the past year. How has that felt? The Trefis Income Solution pays a dividend yield about 3x the S&P 500’s, and in backtests it lost less than the S&P 500 in all 9 big selloffs since 2018. For questions about this article or underlying research, email help@trefis.com.
DYAX Investor Sentiment
Bullish (Long) 39% · Bearish (Short) 61%
260 participants
Related News
- IBM Is Down 21% This Year. What Will It Take to Get IBM Stock Back to $250?
- Berkshire Hathaway Is Up 18% in Its First Year Without Buffett as CEO. Can BRK.B Stock Hit $700 by 2027?
- Nvidia Reports in About an Hour. Options Price an 8.5% Move, Twice What the Stock Has Averaged After Its Last 8 Reports
- Could Your Dell Shares Be Worth $906 Or $114?
- Muddy Waters discloses a short position in Nvidia (NVDA) securities or related derivatives, titled: More China
- After IPO Day: Executing as a Public Company, 6th Palm Beach CorpGov Forum